OAG - Open-Angle Glaucoma

Ophthalmology
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

New World Medical
New World MedicalCA - Rancho Cucamonga
1 program
Canaloplasty DeviceN/A1 trial
Active Trials
NCT05696561Recruiting70Est. Oct 2027
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
Latanoprostene bunod 0.024% QDN/A1 trial
Active Trials
NCT03931317Completed70Est. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
New World MedicalCanaloplasty Device
Bausch + LombLatanoprostene bunod 0.024% QD

Clinical Trials (2)

Total enrollment: 140 patients across 2 trials

NCT05696561New World MedicalCanaloplasty Device

Clinical Trial to Evaluate the Safety and Effectiveness of a Canaloplasty Device in Subjects With Open-Angle Glaucoma

Start: Sep 2025Est. completion: Oct 202770 patients
N/ARecruiting
NCT03931317Bausch + LombLatanoprostene bunod 0.024% QD

Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity

Start: Dec 2018Est. completion: Mar 202370 patients
N/ACompleted

Related Jobs in Ophthalmology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 140 patients
2 companies competing in this space